for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

Latest Trade

341.52USD

Change

-2.56(-0.74%)

Volume

71,959

Today's Range

341.26

 - 

347.97

52 Week Range

271.37

 - 

442.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
344.08
Open
346.25
Volume
71,959
3M AVG Volume
16.23
Today's High
347.97
Today's Low
341.26
52 Week High
442.00
52 Week Low
271.37
Shares Out (MIL)
109.80
Market Cap (MIL)
36,639.30
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Regeneron Pharmaceuticals Inc Earnings Call

Latest Developments

More

Regeneron Says FDA Has Accepted For Priority Review Dupixent® (Dupilumab) For Children Aged 6 To 11 Years With Moderate-To-Severe Atopic Dermatitis

Regeneron Pharmaceuticals- Preliminary U.S. Net Product Sales Of Eylea Injection Of About $4.64 Bln For 2019

Regeneron Announces Encouraging Garetosmab Phase 2 Results In Patients With Ultra-Rare Debilitating Bone Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Contact Info

777 Old Saw Mill River Rd

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board, Director

Leonard S. Schleifer

President, Chief Executive Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

Key Stats

2.44 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

4.9K

2017

5.9K

2018

6.7K

2019(E)

7.8K
EPS (USD)

2016

11.320

2017

16.320

2018

22.840

2019(E)

24.105
Price To Earnings (TTM)
18.64
Price To Sales (TTM)
4.81
Price To Book (MRQ)
3.55
Price To Cash Flow (TTM)
16.02
Total Debt To Equity (MRQ)
6.78
LT Debt To Equity (MRQ)
6.78
Return on Investment (TTM)
19.37
Return on Equity (TTM)
16.88

Latest News

Latest News

U.S. FDA regulator gives new priority review for Sanofi and Regeneron's Dupixent

The U.S. Food & Drug Administration (FDA) regulatory body has accepted for priority review the use of Sanofi and Regeneron's Dupixent product for children aged 6-11 with moderate-to-severe eczema, the companies said.

Regeneron's bone disorder drug reduces lesions in mid-stage study

Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic bone disorder showed a nearly 90% reduction in new lesions compared to placebo, in a mid-stage study.

Regeneron's bone disorder drug reduces bone lesions in mid-stage study

Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic disorder proved more effective than placebo in reducing bone lesions.

U.S. company directors compensated more than ever, but now risk backlash

(This November 8 story corrects spelling of analytics firm ESGauge, paragraph 10)

INSIGHT-US company directors compensated more than ever, but now risk backlash

* S&P 500 directors' average compensation above $300,000 in 2018

Eylea powers Regeneron's third-quarter profit beat; shares rise

Drugmaker Regeneron Pharmaceuticals Inc <REGN.O> beat analysts' estimates for third-quarter profit on Tuesday, boosted by higher demand for its blockbuster eye drug, Eylea, and eczema therapy Dupixent.

Regeneron profit rises nearly 13% on higher demand for eczema drug Dupixent

Nov 5 - Regeneron Pharmaceuticals Inc reported a 12.6% rise in third-quarter profit on Tuesday, boosted by higher sales of its eczema drug, Dupixent.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

Regeneron's Ebola treatment proves superior to rival in trial

Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.

Regeneron beats second-quarter profit estimates on Eylea boost

Regeneron Pharmaceuticals Inc <REGN.O> beat analysts' estimates for second-quarter profit and revenue on Tuesday, boosted by double-digit sales growth of its blockbuster treatment Eylea in the United States.

Regeneron second-quarter revenue beats on Eylea sales

Regeneron Pharmaceuticals Inc reported better-than-expected quarterly revenue on Tuesday, boosted by demand for its blockbuster eye drug, Eylea.

EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases

The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.

REFILE-FDA approves expanded label for Regeneron/Sanofi's Dupixent

The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, the companies said on Wednesday.

FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

U.S. FDA approves expanded label for Regeneron's cholesterol drug

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

Regeneron forays into gene-silencing therapies with Alnylam tie-up

Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.

Alnylam, Regeneron to partner for RNAi treatments

Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.

Regeneron/Sanofi wins U.S. approval for expanded use of skin drug

The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.

Regeneron/Sanofi skin disease drug cleared for use in U.S. teens

The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up